Cidara Therapeutics Form 4: Joshua Resnick Granted Stock Options
Rhea-AI Filing Summary
Cidara Therapeutics (CDTX) – Form 4 insider filing: Director Joshua Resnick reported the receipt of a pro-rated annual stock-option award on 18 June 2025. The grant covers 5,079 options to purchase CDTX common shares at an exercise price of $21.31 per share. These options will vest in full on the earlier of 18 June 2026 or the day prior to the company’s 2026 annual shareholder meeting, and they expire on 17 June 2035.
Resnick holds the options for the benefit of RA Capital Healthcare Fund, L.P. under an arrangement that requires any net proceeds from exercise to be turned over to RA Capital Management. As a result, he disclaims beneficial ownership of both the options and the underlying shares. No open-market purchases or sales of common stock were reported, and Resnick’s direct derivative holdings now total 5,079 options.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine director option grant; negligible governance or valuation impact.
This Form 4 reflects a normal-course, pro-rated annual equity award to a board member. The grant size—5,079 options—is modest, and the one-year cliff vest aligns with standard director compensation practices. Because proceeds flow to RA Capital, the filing is more procedural than economic for the individual. There is no dilution beyond what investors would already expect from the company’s equity incentive plan, and no open-market activity to signal insider sentiment. Overall, the disclosure is a compliance event with neutral impact on governance or share value perceptions.
TL;DR: Small, non-cash option grant—no trading signal for CDTX.
The award’s strike price of $21.31 and 10-year term are typical. Given CDTX’s micro-cap status, the 5,079-share option block is immaterial to float and has no immediate P&L consequences. The absence of any share sale or purchase suggests no directional view by the insider. Investors can treat this as a routine administrative filing with no portfolio-level action warranted.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 5,079 | $0.00 | -- |
Footnotes (1)
- Annual director stock option grant of 11,100 shares is pro-rated based on the number of days served on the Issuer's board of directors prior to the grant date divided by 365 days. The shares subject to the option shall vest on the earlier of (i) June 18, 2026 or (ii) the day prior to the date of the Issuer's 2026 annual meeting of stockholders. Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.
